ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "human papillomavirus (HPV) and vaccines"

  • Abstract Number: 848 • 2013 ACR/ARHP Annual Meeting

    Human Papillomavirus Vaccine Uptake Among Children and Young Adults With Autoimmune Diseases

    Candace H. Feldman1, Linda T. Hiraki2, Joyce Lii3 and Seoyoung C. Kim4, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, 3Department of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 4Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Autoimmune diseases such as lupus and inflammatory bowel disease are associated with increased rates of human papillomavirus (HPV), the most common sexually transmitted disease…
  • Abstract Number: 1820 • 2012 ACR/ARHP Annual Meeting

    Human Papillomavirus Vaccine [Types 6, 11, 16, 18] (Gardasil®) and Autoimmune Disorders: Safety Assessment Using the Pharmacoepidemiologic General Research Extension System

    Lamiae Grimaldi-Bensouda1, Michel Rossignol2, Elodie Aubrun1, Pamela Leighton3, Didier Guillemot4, Alfred Mahr5, Jacques Benichou6, Paul-Henri Lambert7, Bertrand Godeau8 and Lucien Abenhaim9, 1LA-SER, Paris, France, 2LA-SER, Centre for Risk Research, Montreal, Canada, 3LA-SER Europe Ltd., London, United Kingdom, 4Institut Pasteur (PhEMI)/ INSERM U657 & Université Paris-Ile de France Ouest, Paris, France, 5Internal Medicine, Hospital Saint-Louis, Paris, France, 6INSERM U657 Pharmacoepidemiology and evaluation of the impact of health products on human health, France, and Department of Biostatistics, University Hospital of Rouen, Rouen, France, Rouen, France, 7Centre of Vaccinology & neonatal immunology, University of Geneva, Geneva, Switzerland, 8Internal Medicine, University of Paris, AP-HP, Hôpital Mondor Créteil, Creteil, France, 9LA-SER Europe Ltd, London, United Kingdom

    Background/Purpose: This study investigated whether the human papillomavirus (HPV) vaccine [types 6, 11, 16, 18] is associated with a modified risk of autoimmune disorders (AIDs).…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology